Identification

Name
Piroxicam
Accession Number
DB00554  (APRD01187)
Type
Small Molecule
Groups
Approved, Investigational
Description

A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]

Structure
Thumb
Synonyms
  • 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
  • Piroxicam
  • Piroxicam betadex
  • Piroxicamum
  • Pyroxycam
External IDs
CP-16,171
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-piroxicam-cap 10mgCapsule10 mgOralAltimed Pharma Inc.1997-09-242004-08-03Canada
Alti-piroxicam-cap 20mgCapsule20 mgOralAltimed Pharma Inc.1995-12-312004-08-03Canada
Dom-piroxicamSuppository20 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
Dom-piroxicamCapsule20 mgOralDominion Pharmacal1999-10-252016-10-25Canada
Dom-piroxicamCapsule10 mgOralDominion PharmacalNot applicable2016-10-25Canada
Dom-piroxicamSuppository10 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
FeldeneCapsule20 mg/1OralRemedy Repack2012-09-262016-12-23Us
FeldeneCapsule20 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-25Not applicableUs
FeldeneCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-25Not applicableUs
Feldene Cap 10mgCapsule10 mgOralPfizer1981-12-312002-09-06Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Piroxicam Cap 10mgCapsule10 mgOralApotex Corporation1986-12-31Not applicableCanada
Apo Piroxicam Cap 20mgCapsule20 mgOralApotex Corporation1986-12-31Not applicableCanada
FeldeneCapsule20 mg/1OralKeltman Pharmaceuticals Inc.2007-09-18Not applicableUs
PiroxicamCapsule20 mg/1OralSun Pharmaceutical Industries Limited1993-03-12Not applicableUs
PiroxicamCapsule20 mg/1OralAv Kare, Inc.2012-11-28Not applicableUs
PiroxicamCapsule20 mg/1OralMylan Pharmaceuticals2016-09-30Not applicableUs
PiroxicamCapsule10 mg/1OralWest Ward Pharmaceutical2017-08-11Not applicableUs
PiroxicamCapsule10 mg/1OralPack Pharmaceuticals LLC2010-06-15Not applicableUs
PiroxicamCapsule20 mg/1OralUnit Dose Services2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralRemedy Repack2011-04-122016-10-13Us
International/Other Brands
Bruxicam / Dolonex / Erazon / Feldene / Geldène / Improntal / Roxam (Bosnalijek) / Roxiden / Sasulen / Solocalm / Trast
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TherafeldaminePiroxicam + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-03-032016-10-13Us
Categories
UNII
13T4O6VMAM
CAS number
36322-90-4
Weight
Average: 331.346
Monoisotopic: 331.062676609
Chemical Formula
C15H13N3O4S
InChI Key
QYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O

Pharmacology

Indication

For treatment of osteoarthritis and rheumatoid arthritis.

Structured Indications
Pharmacodynamics

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

Mechanism of action

The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Well absorbed following oral administration.

Volume of distribution
  • 0.14 L/kg
Protein binding
Not Available
Metabolism

Renal

Route of elimination

Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.

Half life

30 to 86 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Piroxicam Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*3Not Available1075A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabPiroxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Piroxicam can be increased when it is combined with Abiraterone.Approved
AcebutololPiroxicam may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acemetacin.Approved
AcenocoumarolPiroxicam may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinPiroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Piroxicam.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.Approved
AliskirenPiroxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alminoprofen.Experimental
AlprenololPiroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Piroxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Amcinonide.Approved
AmikacinPiroxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePiroxicam may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Piroxicam.Approved
AmrubicinPiroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodPiroxicam may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anisodamine.Investigational
annamycinPiroxicam may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.Approved
Antithrombin III humanPiroxicam may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPiroxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Piroxicam is combined with Apocynin.Investigational
ApramycinPiroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Piroxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinPiroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinPiroxicam may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPiroxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPiroxicam may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Atamestane.Investigational
AtenololPiroxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.Approved
BalsalazidePiroxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminPiroxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPiroxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPiroxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Piroxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololPiroxicam may decrease the antihypertensive activities of Betaxolol.Approved
BevantololPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
BisoprololPiroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPiroxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPiroxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bucillamine.Investigational
BucindololPiroxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bufexamac.Experimental
BufuralolPiroxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bumadizone.Experimental
BumetanidePiroxicam may decrease the diuretic activities of Bumetanide.Approved
BupranololPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Piroxicam.Experimental
CapecitabineThe metabolism of Piroxicam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Piroxicam.Approved
CarbamazepineThe metabolism of Piroxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Piroxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPiroxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPiroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Piroxicam can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPiroxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.Approved
CertoparinPiroxicam may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.Approved
CholecalciferolThe metabolism of Piroxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.Approved
CinoxacinPiroxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidPiroxicam may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Piroxicam.Vet Approved
CloranololPiroxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Piroxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Piroxicam can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Piroxicam is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Piroxicam.Experimental
CyclosporinePiroxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Piroxicam is combined with D-Limonene.Investigational
Dabigatran etexilatePiroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.Approved
DalteparinPiroxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPiroxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPiroxicam may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinPiroxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Piroxicam.Experimental
DelavirdineThe metabolism of Piroxicam can be decreased when combined with Delavirdine.Approved
DesirudinPiroxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Piroxicam.Approved
DextranPiroxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Piroxicam may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Piroxicam may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Piroxicam may increase the anticoagulant activities of Dextran 75.Approved
DibekacinPiroxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Piroxicam.Approved, Vet Approved
DicoumarolPiroxicam may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.Approved
DihydrostreptomycinPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Piroxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Piroxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Piroxicam.Approved
DosulepinThe metabolism of Piroxicam can be decreased when combined with Dosulepin.Approved
DoxorubicinPiroxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePiroxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Piroxicam is combined with E-6201.Investigational
Edetic AcidPiroxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPiroxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Piroxicam can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Piroxicam.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Piroxicam.Approved
EnoxacinPiroxicam may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinPiroxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Piroxicam.Experimental
EpanololPiroxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Epirizole.Approved
EpirubicinPiroxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePiroxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilin.Approved
EsmololPiroxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone sulfate.Approved
Etacrynic acidPiroxicam may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etofenamate.Approved
EtravirineThe metabolism of Piroxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Piroxicam is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Felbinac.Experimental
FelodipineThe metabolism of Piroxicam can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Piroxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Feprazone.Experimental
Ferulic acidPiroxicam may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Piroxicam.Approved
FleroxacinPiroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Piroxicam.Approved, Withdrawn
FloxuridineThe metabolism of Piroxicam can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with fluasterone.Investigational
FluconazoleThe metabolism of Piroxicam can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fludrocortisone.Approved
FluindionePiroxicam may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePiroxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Piroxicam can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Piroxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Piroxicam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Piroxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Piroxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxPiroxicam may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPiroxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.Approved
FosphenytoinThe metabolism of Piroxicam can be increased when combined with Fosphenytoin.Approved
FramycetinPiroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePiroxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexatePiroxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPiroxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPiroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Piroxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Piroxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPiroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPiroxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPiroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APiroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Piroxicam may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinPiroxicam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Piroxicam is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Piroxicam is combined with HE3286.Investigational
HeparinPiroxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Higenamine.Investigational
HydralazinePiroxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.Approved
Hygromycin BPiroxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.Approved
IdarubicinPiroxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxPiroxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Piroxicam.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.Approved
IndenololPiroxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Piroxicam can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Indoprofen.Withdrawn
INNO-206Piroxicam may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Piroxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinPiroxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Piroxicam is combined with Istaroxime.Investigational
KanamycinPiroxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Piroxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.Approved
LabetalolPiroxicam may decrease the antihypertensive activities of Labetalol.Approved
LandiololPiroxicam may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Piroxicam can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Piroxicam.Investigational
LeflunomideThe metabolism of Piroxicam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinPiroxicam may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPiroxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololPiroxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPiroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Piroxicam.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Piroxicam.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Piroxicam.Approved
LobeglitazoneThe metabolism of Piroxicam can be decreased when combined with Lobeglitazone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.Approved
LosartanThe metabolism of Piroxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Piroxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Piroxicam.Approved, Investigational
LumacaftorThe serum concentration of Piroxicam can be increased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Piroxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Piroxicam can be decreased when combined with Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.Approved
ME-609The risk or severity of adverse effects can be increased when Piroxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.Approved
MelagatranPiroxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.Approved, Vet Approved
MepindololPiroxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazinePiroxicam may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPiroxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.Approved
MetoprololPiroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePiroxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinPiroxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Piroxicam can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Piroxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Piroxicam.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.Approved
NadololPiroxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPiroxicam may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPiroxicam may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naftifine.Approved
Nalidixic AcidPiroxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 1022.Investigational
NeaminePiroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinPiroxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPiroxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nepafenac.Approved
NetilmicinPiroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Piroxicam can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Piroxicam can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nitroaspirin.Investigational
NorfloxacinPiroxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.Approved
OlsalazinePiroxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Piroxicam.Investigational
OmeprazoleThe metabolism of Piroxicam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Orgotein.Vet Approved
OtamixabanPiroxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.Approved
Oxolinic acidPiroxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPiroxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Paramethasone.Approved
ParomomycinPiroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Parthenolide.Investigational
PazufloxacinPiroxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPiroxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPiroxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfatePiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Piroxicam.Approved
PhenindionePiroxicam may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Piroxicam can be increased when combined with Phenobarbital.Approved
PhenprocoumonPiroxicam may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Piroxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.Approved, Investigational
PindololPiroxicam may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Piroxicam can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidPiroxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinPiroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePiroxicam may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.Investigational
Piromidic acidPiroxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PirprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirprofen.Experimental
PlazomicinPiroxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinPiroxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam.Approved
PractololPiroxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Piroxicam.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Piroxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Piroxicam can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Propacetamol.Approved
PropranololPiroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Piroxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Piroxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Piroxicam.Vet Approved
Protein CPiroxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanPiroxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePiroxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPiroxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Piroxicam is combined with PTC299.Investigational
PuromycinPiroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Piroxicam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.Approved
QuinineThe metabolism of Piroxicam can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Piroxicam.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Experimental, Investigational
ReviparinPiroxicam may increase the anticoagulant activities of Reviparin.Approved
RibostamycinPiroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Piroxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Piroxicam can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.Approved, Investigational
RivaroxabanPiroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe metabolism of Piroxicam can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinPiroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinPiroxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinPiroxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Piroxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Piroxicam.Investigational
SecobarbitalThe metabolism of Piroxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Piroxicam is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Piroxicam is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Piroxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinPiroxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPiroxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Piroxicam.Approved
SorafenibThe metabolism of Piroxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPiroxicam may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPiroxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPiroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinPiroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Piroxicam.Approved
SpironolactonePiroxicam may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Piroxicam is combined with SRT501.Investigational
StreptomycinPiroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPiroxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Piroxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.Approved
SulodexidePiroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Piroxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suxibuzone.Experimental
TacrolimusPiroxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Piroxicam.Approved
TalinololPiroxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Piroxicam.Approved
TamoxifenThe metabolism of Piroxicam can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Piroxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.Approved, Investigational
TemafloxacinPiroxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Piroxicam.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Piroxicam can be decreased when combined with Teriflunomide.Approved
TertatololPiroxicam may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Piroxicam can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiludronic acid.Approved, Vet Approved
TimololPiroxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tixocortol.Approved
TobramycinPiroxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.Approved
TopiroxostatThe metabolism of Piroxicam can be decreased when combined with Topiroxostat.Approved
TorasemidePiroxicam may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Piroxicam.Approved
TranilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triamcinolone.Approved, Vet Approved
TriamterenePiroxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triptolide.Investigational
TrovafloxacinPiroxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinPiroxicam may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Piroxicam.Approved
Valproic AcidThe metabolism of Piroxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinPiroxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Piroxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Piroxicam.Approved
VoriconazoleThe metabolism of Piroxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPiroxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPiroxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Piroxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Piroxicam.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinPiroxicam may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinPiroxicam may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food. Avoid alcohol.

References

Synthesis Reference

Paul D. Weeks, "3-Hydroxy 2-methyl benzisothiazolines as intermediates in production of piroxicam." U.S. Patent US4376204, issued April, 1982.

US4376204
General References
Not Available
External Links
Human Metabolome Database
HMDB14694
KEGG Drug
D00127
KEGG Compound
C01608
PubChem Compound
54676228
PubChem Substance
46505225
ChemSpider
10442653
BindingDB
85245
ChEBI
8249
ChEMBL
CHEMBL527
Therapeutic Targets Database
DAP000181
PharmGKB
PA450985
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Piroxicam
ATC Codes
S01BC06 — PiroxicamM02AA07 — PiroxicamM01AC01 — Piroxicam
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (74.3 KB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentRenal Colic1
2CompletedNot AvailablePostcoital Contraception1
2CompletedTreatmentOsteoarthritis of the Knees1
4CompletedSupportive CareCytochrome P450 CYP2C9 Enzyme Deficiency / Impacted Third Molar Tooth / Other Surgical Procedures / Pain1
4CompletedTreatmentDysmenorrhea1
4CompletedTreatmentHypertensive1
4CompletedTreatmentPrimary Dysmenorrhoea1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1

Pharmacoeconomics

Manufacturers
  • Akorn inc
  • Pfizer laboratories div pfizer inc
  • Egis pharmaceuticals
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Roxane laboratories inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral20 mg
SuppositoryRectal10 mg
SuppositoryRectal20 mg
CapsuleOral10 mg/1
CapsuleOral20 mg/1
TabletOral10 mg
Kit
Prices
Unit descriptionCostUnit
Piroxicam powder13.16USD g
Akten 3.5% drops7.5USD ml
Feldene 20 mg capsule4.93USD capsule
Feldene 10 mg capsule2.82USD capsule
Piroxicam 20 mg capsule2.69USD capsule
Pms-Piroxicam 20 mg Suppository1.82USD suppository
Piroxicam 10 mg capsule1.44USD capsule
Apo-Piroxicam 20 mg Capsule0.75USD capsule
Novo-Pirocam 20 mg Capsule0.75USD capsule
Nu-Pirox 20 mg Capsule0.75USD capsule
Apo-Piroxicam 10 mg Capsule0.43USD capsule
Gen-Piroxicam 10 mg Capsule0.43USD capsule
Novo-Pirocam 10 mg Capsule0.43USD capsule
Nu-Pirox 10 mg Capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)198-200 °CPhysProp
water solubility23 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.06AVDEEF,A (1997)
logS-4.16ADME Research, USCD
Caco2 permeability-4.45ADME Research, USCD
pKa6.3SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP2.2ALOGPS
logP0.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.76ChemAxon
pKa (Strongest Basic)3.79ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.04 m3·mol-1ChemAxon
Polarizability32.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9898
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5786
P-glycoprotein inhibitor INon-inhibitor0.7285
P-glycoprotein inhibitor IINon-inhibitor0.7453
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateSubstrate0.6437
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.9086
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8709
Ames testNon AMES toxic0.8767
CarcinogenicityNon-carcinogens0.7612
BiodegradationNot ready biodegradable0.923
Rat acute toxicity3.1545 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0019000000-0d247806d6203409cc16
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014j-0591000000-7d11d429795ac27fa093
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000t-0910000000-42d97ebe5da8190aa202
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001m-2900000000-32c34cd63ced296fee89
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00kf-5900000000-1d4473d813b920140b81
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00lr-0009000000-9e65aa6e4b407ea80734
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000f-3984000000-e855ded4bfe08c600884
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-007c-3900000000-fb37337024398fe8044d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-006t-9600000000-db1bff24de3a9b89b68d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00r2-9200000000-22caea8b3219419be51f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-01vk-6900000000-a75ce07d3bc58c9e773b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-5829000000-bfa87ed6f54b64fe3942
MS/MS Spectrum - , positiveLC-MS/MSsplash10-1000-1698000000-9bfc929b8cee2ec1d841
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-6911100000-64e355e5e08c884173b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Alpha amino acids and derivatives / Pyridines and derivatives / Organosulfonamides / 1,2-thiazines / Benzenoids / Imidolactams / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Carboximidic acids
show 6 more
Substituents
Alpha-amino acid or derivatives / Benzothiazine / Ortho-thiazine / Pyridine / Organosulfonic acid amide / Benzenoid / Imidolactam / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, pyridines, benzothiazine (CHEBI:8249)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
  5. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:23